MX2015007135A - Novedosos derivados de bencimidazol como antagonistas de ep4. - Google Patents
Novedosos derivados de bencimidazol como antagonistas de ep4.Info
- Publication number
- MX2015007135A MX2015007135A MX2015007135A MX2015007135A MX2015007135A MX 2015007135 A MX2015007135 A MX 2015007135A MX 2015007135 A MX2015007135 A MX 2015007135A MX 2015007135 A MX2015007135 A MX 2015007135A MX 2015007135 A MX2015007135 A MX 2015007135A
- Authority
- MX
- Mexico
- Prior art keywords
- benzimidazole derivatives
- antagonists
- novel benzimidazole
- novel
- indications
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención se refiere a novedosos derivados de bencimidazol de la fórmula general (I), a procedimientos para su preparación, así como su uso para la preparación de agentes farmacéuticos para el tratamiento de enfermedades e indicaciones que están relacionadas con el receptor EP4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195849 | 2012-12-06 | ||
| PCT/EP2013/075309 WO2014086739A1 (de) | 2012-12-06 | 2013-12-03 | Neuartige benzimidazolderivate als ep4-antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007135A true MX2015007135A (es) | 2016-02-05 |
Family
ID=47325927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007135A MX2015007135A (es) | 2012-12-06 | 2013-12-03 | Novedosos derivados de bencimidazol como antagonistas de ep4. |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9708311B2 (es) |
| EP (1) | EP2928884B1 (es) |
| JP (1) | JP6367822B2 (es) |
| KR (1) | KR20150092248A (es) |
| CN (1) | CN104854098B (es) |
| AP (1) | AP3862A (es) |
| AR (1) | AR093840A1 (es) |
| AU (1) | AU2013354226B2 (es) |
| BR (1) | BR112015012555B1 (es) |
| CA (1) | CA2893630C (es) |
| CL (1) | CL2015001508A1 (es) |
| CR (1) | CR20150296A (es) |
| CU (1) | CU20150056A7 (es) |
| CY (1) | CY1119200T1 (es) |
| DK (1) | DK2928884T3 (es) |
| EA (1) | EA028830B1 (es) |
| EC (1) | ECSP15022555A (es) |
| ES (1) | ES2637738T3 (es) |
| GT (1) | GT201500138A (es) |
| HR (1) | HRP20171200T1 (es) |
| IL (1) | IL239026A0 (es) |
| JO (1) | JO3431B1 (es) |
| LT (1) | LT2928884T (es) |
| MA (1) | MA38146B1 (es) |
| ME (1) | ME02950B (es) |
| MX (1) | MX2015007135A (es) |
| MY (1) | MY175272A (es) |
| NI (1) | NI201500077A (es) |
| NZ (1) | NZ707825A (es) |
| PE (1) | PE20151065A1 (es) |
| PH (1) | PH12015501289B1 (es) |
| PL (1) | PL2928884T3 (es) |
| PT (1) | PT2928884T (es) |
| RS (1) | RS56121B1 (es) |
| SI (1) | SI2928884T1 (es) |
| TN (1) | TN2015000250A1 (es) |
| TW (1) | TWI613198B (es) |
| UA (1) | UA115576C2 (es) |
| UY (1) | UY35177A (es) |
| WO (1) | WO2014086739A1 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10053454B2 (en) | 2013-02-27 | 2018-08-21 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| CA2925862A1 (en) | 2013-10-01 | 2015-04-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| SMT201800643T1 (it) * | 2013-12-24 | 2019-01-11 | Bristol Myers Squibb Co | Composti triciclici come agenti anticancro |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| CN104326937B (zh) * | 2014-09-03 | 2016-08-24 | 天津市肿瘤研究所 | 抗肿瘤化合物及其医药用途 |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| HRP20211683T1 (hr) | 2016-09-30 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| PT3625228T (pt) | 2017-05-18 | 2021-09-16 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores dos recetores de pge2 |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| LT3625222T (lt) | 2017-05-18 | 2021-11-10 | Idorsia Pharmaceuticals Ltd | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai |
| LT3625224T (lt) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | N-pakeistieji indolo dariniai |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CA3107023A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
| CN113527206B (zh) * | 2020-04-17 | 2022-12-30 | 上海中泽医药科技有限公司 | 一种苯并氮杂环类化合物、其制备方法及用途 |
| CN120247907A (zh) * | 2020-05-04 | 2025-07-04 | 大塚制药株式会社 | Iap拮抗剂化合物和中间体及其合成方法 |
| JPWO2022102731A1 (es) | 2020-11-13 | 2022-05-19 | ||
| US12016847B2 (en) | 2021-03-12 | 2024-06-25 | Bristol-Myers Squibb Company | Methods of treating prostate cancer |
| KR102708701B1 (ko) * | 2021-12-27 | 2024-09-24 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체의 제조방법 |
| CN116789646B (zh) * | 2023-07-12 | 2025-07-08 | 广西医科大学 | 咔唑-苯并咪唑偶联类化合物及其应用 |
| WO2025135108A1 (ja) * | 2023-12-22 | 2025-06-26 | Ａｇｃ株式会社 | 新規なｅｐ４アンタゴニスト |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514403A (en) | 1999-12-27 | 2002-10-25 | Japan Tobacco Inc | Fused-ring compounds and use thereof as drugs |
| EE05533B1 (et) | 2000-01-18 | 2012-04-16 | Schering Aktiengesellschaft | Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja strogeeni ning nende kasutamine |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| MXPA04009243A (es) | 2002-04-12 | 2005-06-08 | Pfizer | Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6. |
| CN1671672A (zh) * | 2002-07-31 | 2005-09-21 | 欧洲凯尔特股份有限公司 | 芳基取代的苯并咪唑类及其作为钠通道阻滞剂的用途 |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2004046143A1 (en) | 2002-11-15 | 2004-06-03 | Tibotec Pharmaceuticals Ltd. | Substituted indolepyridinium as anti-infective compounds |
| US6949564B2 (en) | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
| CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| JP2006522070A (ja) | 2003-04-03 | 2006-09-28 | ニューロサーチ、アクティーゼルスカブ | ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法 |
| TW200512147A (en) | 2003-07-25 | 2005-04-01 | Black Clawson Converting Machinery Inc | Method and apparatus for splicing webs |
| AP2006003534A0 (en) | 2003-09-03 | 2006-04-30 | Pfizer | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. |
| WO2005102389A2 (en) | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| JP2008504233A (ja) | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
| JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
| KR20070114123A (ko) * | 2005-01-19 | 2007-11-29 | 바이올리폭스 에이비 | 염증 치료에 유용한 인돌 |
| JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| US7732447B2 (en) * | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
| GB0614066D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| EP2054401B1 (en) | 2006-08-11 | 2013-05-01 | Merck Canada Inc. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| WO2008104055A1 (en) | 2007-02-26 | 2008-09-04 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| EP2185534A1 (en) | 2007-08-09 | 2010-05-19 | Merck Sharp & Dohme Corp. | Process for making thiophene carboxamide derivative |
| US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| WO2010117639A2 (en) | 2009-03-31 | 2010-10-14 | The Texas A&M University System | Inhibition of prostglandin e2 receptors for the treatment of endometriosis |
| WO2010124097A2 (en) | 2009-04-22 | 2010-10-28 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| MX341482B (es) * | 2010-02-22 | 2016-08-22 | Raqualia Pharma Inc | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
-
2013
- 2013-03-12 UA UAA201506493A patent/UA115576C2/uk unknown
- 2013-12-03 EP EP13798684.0A patent/EP2928884B1/de active Active
- 2013-12-03 MA MA38146A patent/MA38146B1/fr unknown
- 2013-12-03 KR KR1020157017666A patent/KR20150092248A/ko not_active Abandoned
- 2013-12-03 DK DK13798684.0T patent/DK2928884T3/en active
- 2013-12-03 PE PE2015000750A patent/PE20151065A1/es active IP Right Grant
- 2013-12-03 EA EA201591087A patent/EA028830B1/ru not_active IP Right Cessation
- 2013-12-03 PL PL13798684T patent/PL2928884T3/pl unknown
- 2013-12-03 AU AU2013354226A patent/AU2013354226B2/en active Active
- 2013-12-03 JP JP2015545771A patent/JP6367822B2/ja active Active
- 2013-12-03 ME MEP-2017-181A patent/ME02950B/me unknown
- 2013-12-03 SI SI201330742T patent/SI2928884T1/sl unknown
- 2013-12-03 PT PT137986840T patent/PT2928884T/pt unknown
- 2013-12-03 CA CA2893630A patent/CA2893630C/en active Active
- 2013-12-03 WO PCT/EP2013/075309 patent/WO2014086739A1/de not_active Ceased
- 2013-12-03 RS RS20170790A patent/RS56121B1/sr unknown
- 2013-12-03 US US14/649,896 patent/US9708311B2/en active Active
- 2013-12-03 ES ES13798684.0T patent/ES2637738T3/es active Active
- 2013-12-03 CN CN201380063594.4A patent/CN104854098B/zh active Active
- 2013-12-03 MY MYPI2015701808A patent/MY175272A/en unknown
- 2013-12-03 LT LTEP13798684.0T patent/LT2928884T/lt unknown
- 2013-12-03 BR BR112015012555-7A patent/BR112015012555B1/pt active IP Right Grant
- 2013-12-03 MX MX2015007135A patent/MX2015007135A/es active IP Right Grant
- 2013-12-03 NZ NZ707825A patent/NZ707825A/en unknown
- 2013-12-03 AP AP2015008463A patent/AP3862A/en active
- 2013-12-03 HR HRP20171200TT patent/HRP20171200T1/hr unknown
- 2013-12-04 JO JOP/2013/0349A patent/JO3431B1/ar active
- 2013-12-06 AR ARP130104542A patent/AR093840A1/es unknown
- 2013-12-06 TW TW102144979A patent/TWI613198B/zh not_active IP Right Cessation
- 2013-12-06 UY UY0001035177A patent/UY35177A/es unknown
-
2015
- 2015-05-27 IL IL239026A patent/IL239026A0/en active IP Right Grant
- 2015-06-04 CL CL2015001508A patent/CL2015001508A1/es unknown
- 2015-06-04 CU CU2015000056A patent/CU20150056A7/es unknown
- 2015-06-05 TN TNP2015000250A patent/TN2015000250A1/fr unknown
- 2015-06-05 EC ECIEPI201522555A patent/ECSP15022555A/es unknown
- 2015-06-05 CR CR20150296A patent/CR20150296A/es unknown
- 2015-06-05 NI NI201500077A patent/NI201500077A/es unknown
- 2015-06-05 GT GT201500138A patent/GT201500138A/es unknown
- 2015-06-05 PH PH12015501289A patent/PH12015501289B1/en unknown
-
2017
- 2017-08-10 CY CY20171100862T patent/CY1119200T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501289B1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| NZ743274A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| MX348451B (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12. | |
| MY175854A (en) | Novel quinolone derivatives | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| TN2013000420A1 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
| MX2013013436A (es) | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. | |
| IN2015DN00950A (es) | ||
| MX2016011901A (es) | Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
| MX348841B (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
| TN2013000441A1 (en) | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | |
| MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. | |
| IN2015DN02660A (es) | ||
| CU20140058A7 (es) | Nuevos 2h-indizoles como antagonistas del receptor ep-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: BAYER ANIMAL HEALTH GMBH |